Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Hepatitis B Immunoglobulin

Hepatitis B Immunoglobulin: An In-Depth Overview

Introduction

Hepatitis B is a significant global health concern, caused by the Hepatitis B virus (HBV), which primarily infects the liver, leading to various conditions ranging from acute hepatitis to chronic liver disease and even liver cancer. While vaccination against hepatitis B has been a breakthrough in reducing the incidence of the virus, Hepatitis B Immunoglobulin (HBIG) plays a vital role in the prevention and treatment of hepatitis B infections, particularly for individuals exposed to the virus or at high risk. Hepatitis B Immunoglobulin (HBIG) is a solution of human antibodies derived from the plasma of donors who have a high concentration of antibodies to the HBV surface antigen (anti-HBs).

Hepatitis B Immunoglobulin (HBIG)

Hepatitis B Immunoglobulin is a specialized blood product that contains immunoglobulins (antibodies) specific to the Hepatitis B virus (HBV). It is extracted from the plasma of donors who have previously been exposed to HBV and have developed a strong immune response. The immunoglobulin works by providing passive immunity to individuals who have been exposed to the virus or are at high risk of exposure. The antibodies in HBIG neutralize the HBV virus and prevent it from infecting liver cells, effectively providing immediate protection against HBV infection. This is particularly beneficial in scenarios where a person has been recently exposed to the virus or where the individual’s immune system may not be able to mount an adequate defense on its own.

Mechanism of Action

Hepatitis B Immunoglobulin contains high levels of anti-HBs antibodies, which specifically target the HBV surface antigen (HBsAg). The surface antigen of HBV is a protein found on the viral envelope, and the presence of antibodies against it can effectively neutralize the virus and prevent it from entering liver cells.

How HBIG Works:

  1. Neutralization of the Virus: The anti-HBs antibodies present in HBIG bind to the surface antigen of the virus. This binding prevents the virus from attaching to and entering liver cells, thereby blocking infection.

  2. Prevention of Viral Replication: Once the virus is neutralized, it cannot replicate and spread within the body, which helps to reduce the viral load and prevents further liver damage.

  3. Passive Immunity: Since HBIG contains pre-formed antibodies, it provides immediate passive immunity, which is essential in cases where an individual is exposed to the virus but has not yet developed their own immune response. This is in contrast to active immunity, which is achieved through vaccination.

HBIG does not provide long-term immunity, and its protective effects last for a limited time, which is why it is often used in conjunction with the hepatitis B vaccine for long-term protection.

Clinical Uses of Hepatitis B Immunoglobulin

Hepatitis B Immunoglobulin is widely used in various clinical settings to provide immediate protection against HBV infection. It is most commonly administered in the following situations:

1. Post-Exposure Prophylaxis (PEP)

After potential exposure to the Hepatitis B virus, especially in high-risk situations, HBIG can be given to individuals to prevent infection. Some common post-exposure scenarios include:

  • Needle Stick Injuries: Healthcare workers or others who are accidentally exposed to blood or body fluids containing HBV.

  • Sexual Exposure: Individuals who have had unprotected sexual contact with someone infected with HBV.

  • Perinatal Exposure: Babies born to mothers who are HBV positive, particularly if the mother’s viral load is high or she is HBV e-antigen positive.

In these cases, HBIG is typically administered within 24 hours of exposure, although it can still be effective if given within 7 days.

2. Prevention of Vertical Transmission

One of the most critical uses of HBIG is the prevention of vertical transmission of Hepatitis B from mother to child during childbirth. This is particularly important in HBV-infected pregnant women, as the virus can be passed from mother to child during labor and delivery.

For newborns of HBV-positive mothers, HBIG is given along with the hepatitis B vaccine within 12 hours of birth. This combination significantly reduces the likelihood of the infant developing chronic hepatitis B infection later in life.

3. Treatment of Chronic Hepatitis B

In individuals who are already infected with HBV and have not responded to standard antiviral treatments, HBIG may be used in specific cases of chronic hepatitis B to provide additional immune support and potentially reduce the viral load. HBIG is typically administered alongside antiviral therapy, such as tenofovir or entecavir, to enhance the therapeutic effects.

In liver transplant recipients who have a history of chronic HBV infection, HBIG is often administered post-transplant to prevent reinfection of the liver graft.

4. Immunosuppressed Patients

HBIG is also used in immunosuppressed patients, such as those undergoing chemotherapy or organ transplants, who may be at a higher risk of contracting HBV due to a weakened immune system. The immunoglobulin provides temporary protection until the immune system can recover or until the individual receives a vaccination.

Administration and Dosage

Hepatitis B Immunoglobulin is administered via intramuscular injection (IM), though in some cases, it may be given intravenously (IV) depending on the clinical situation. The exact dose and frequency of administration depend on the age, immune status, and risk level of the individual.

Post-Exposure Prophylaxis:

  • Adults: Typically, 500 to 1,000 IU of HBIG is administered within 24 hours of exposure. A second dose may be given a month later, depending on the situation.

  • Infants (Newborns of HBV-positive Mothers): 0.5 mL of HBIG is given within 12 hours of birth, followed by the first dose of the hepatitis B vaccine.

Chronic Hepatitis B:

In individuals with chronic hepatitis B who require HBIG for additional immune support, the exact dosage may vary. It is usually given every month in high-risk liver transplant recipients or those with a history of hepatitis B infection.

Side Effects and Safety Concerns

While HBIG is generally safe and well-tolerated, it is not without potential side effects. The most common adverse reactions are mild and include:

1. Local Reactions:

  • Pain or redness at the injection site.

  • Swelling or tenderness in the area of administration.

2. Systemic Reactions:

  • Fever or chills.

  • Headache, fatigue, or dizziness.

  • Nausea or vomiting (less common).

3. Allergic Reactions:

  • Allergic reactions are rare but can occur, especially in individuals who have sensitivities to blood products. Reactions can include rash, hives, or more severe reactions such as anaphylaxis (although very rare).

4. Transmission of Infectious Agents:

As with all blood-derived products, there is a theoretical risk of transmission of infectious agents despite rigorous screening of donors. This is an inherent risk of all human-derived products, though it is minimized through careful screening and treatment processes.

Importance of HBIG in the Global Context

Hepatitis B remains a major public health challenge, with an estimated 296 million people worldwide living with chronic hepatitis B infection. It is one of the leading causes of liver cirrhosis and liver cancer, particularly in areas with high endemicity, such as Asia, Africa, and parts of Eastern Europe. Hepatitis B Immunoglobulin (HBIG), along with the hepatitis B vaccine, has been instrumental in reducing the spread of HBV, particularly in high-risk populations.

Prevention and Control of Hepatitis B:

HBIG has been a key tool in the prevention and control of hepatitis B, especially in high-risk groups, such as healthcare workers, infants born to infected mothers, and those with occupational exposure. Its ability to provide immediate protection after exposure significantly reduces the risk of developing chronic HBV and its associated complications.

Conclusion

Hepatitis B Immunoglobulin (HBIG) is a vital tool in the fight against hepatitis B infection, providing passive immunity and preventing the spread of the virus in exposed individuals. Its role in post-exposure prophylaxis, vertical transmission prevention, and supportive treatment in chronic HBV has saved countless lives and prevented the devastating consequences of chronic liver disease. While it is generally safe, like all medical treatments, it comes with the potential for side effects and requires careful administration. As the world continues its battle against Hepatitis B, the combination of vaccination and the use of HBIG remains a cornerstone of public health strategies aimed at eliminating HBV and improving global liver health.